121 related articles for article (PubMed ID: 37635376)
41. Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer: A Meta-Analysis.
Hu L; Du S; Guo W; Chen D; Li Y
Int J Gynecol Cancer; 2016 Feb; 26(2):331-40. PubMed ID: 26807564
[TBL] [Abstract][Full Text] [Related]
42. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of serum HE4 level in the management of endometrial cancer: A pilot study.
Rajadevan N; McNally O; Neesham D; Richards A; Naaman Y
Aust N Z J Obstet Gynaecol; 2021 Apr; 61(2):284-289. PubMed ID: 33528032
[TBL] [Abstract][Full Text] [Related]
44. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
Chen W; Shan B; Zhou S; Yang H; Ye S
BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
[TBL] [Abstract][Full Text] [Related]
45. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
46. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.
Manganaro L; Anastasi E; Porpora MG; Vinci V; Saldari M; Bernardo S; Ballesio L; Sollazzo P; Pecorella I; Recchia N; Stracci F; Panici PB; Angeloni A; Catalano C; Scialpi M
Anticancer Res; 2015 Nov; 35(11):6341-51. PubMed ID: 26504074
[TBL] [Abstract][Full Text] [Related]
47. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
48. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
50. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.
Omer B; Genc S; Takmaz O; Dirican A; Kusku-Kiraz Z; Berkman S; Gurdol F
Tumour Biol; 2013 Oct; 34(5):2645-50. PubMed ID: 23640061
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.
Bie Y; Zhang Z
World J Surg Oncol; 2014 May; 12():169. PubMed ID: 24885319
[TBL] [Abstract][Full Text] [Related]
52. D-dimer, Fibrinogen and Tumor Marker Levels in Patients with benign and Malignant Ovarian Tumors.
Farzaneh F; Salimnezhad M; Hosseini MS; Ashraf Ganjouee T; Arab M; Talayeh M
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4263-4268. PubMed ID: 38156862
[TBL] [Abstract][Full Text] [Related]
53. Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours.
Wang R; Li X; Li S; Fang S; Zhao C; Yang H; Yang Z
Acta Radiol; 2023 Feb; 64(2):821-828. PubMed ID: 35291856
[TBL] [Abstract][Full Text] [Related]
54. [A preliminary study of retinoblastoma-related serum tumor markers].
Liu ZP; Zhou KY; Chen LL; Xiao ZH; Chen YZ
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Mar; 19(3):318-321. PubMed ID: 28302204
[TBL] [Abstract][Full Text] [Related]
55. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
[TBL] [Abstract][Full Text] [Related]
57. Application Value of Real-Time Ultrasonic Elastograph with Serum Human Epididymis Protein 4, Interleukin-33, and Carbohydrate Antigen 153 in Diagnosis of Early Cervical Cancer.
Guo M; Liang L; Wu L; Xie D; Li J
J Healthc Eng; 2022; 2022():4880874. PubMed ID: 35449844
[TBL] [Abstract][Full Text] [Related]
58. Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: a retrospective study.
Jiaao L; Wanli G; Kai Z; Feng G; Yunpeng P
Eur J Med Res; 2023 Oct; 28(1):436. PubMed ID: 37848965
[TBL] [Abstract][Full Text] [Related]
59. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
60. HE4 is an independent prognostic marker in endometrial cancer patients.
Mutz-Dehbalaie I; Egle D; Fessler S; Hubalek M; Fiegl H; Marth C; Widschwendter A
Gynecol Oncol; 2012 Aug; 126(2):186-91. PubMed ID: 22525819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
